Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans

European Journal of Endocrinology

Volumn 169, Issue 6, 2013, Pages 829-834

  Vamvini, Maria T ^a   Aronis, Konstantinos N ^a,b,c   Panagiotou, Grigorios ^a   Huh, Joo Young ^a   Chamberland, John P ^a   Brinkoetter, Mary T ^a   Petrou, Michael ^d   Christophi, Costas A ^e   Kales, Stefanos N ^f   Christiani, David C ^f   Mantzoros, Christos S ^a,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Cyprus Anti Doping Authority (CyADA) 'Lefkotheo'   (Cyprus)

^e CYPRUS UNIVERSITY OF TECHNOLOGY   (Cyprus)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; CYTOKINE; FOLLISTATIN; IRISIN; MESSENGER RNA; MYOSTATIN; UNCLASSIFIED DRUG; ACTIVIN; FIBRONECTIN; FNDC5 PROTEIN, HUMAN; FST PROTEIN, HUMAN; MSTN PROTEIN, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PPARGC1A PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; FNDC5 GENE; FST GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LEAN BODY WEIGHT; MALE; MORBID OBESITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AGED; BLOOD; CROSS-SECTIONAL STUDY; CYPRUS; GENETICS; METABOLISM; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION; SKELETAL MUSCLE;

ACTIVINS; ADULT; AGED; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; CYPRUS; FEMALE; FIBRONECTINS; FOLLISTATIN; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYOSTATIN; OBESITY, MORBID; PPAR GAMMA; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 84888257596     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0276     Document Type: Article

References (29)

1. Welc SS & Clanton TL. The regulation of interleukin-6 implicates skeletal muscle as an integrative stress sensor and endocrine organ. Experimental Physiology 2013 98 359-371. (doi:10.1113/expphysiol.2012.068189)
2. Henriksen T, Green C & Pedersen BK. Myokines in myogenesis and health. Recent Patents on Biotechnology 2012 6 167-171. (doi:10.2174/ 1872208311206030167)
3. Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Bostrom EA, Choi JH, Long JZ et al. A PGC1-adependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012 481 463-468. (doi:10.1038/nature10777)
4. Sanchis-Gomar F, Lippi G, Mayero S, Perez-Quilis C & Garcia-Gimenez JL. Irisin: a new potential hormonal target for the treatment of obesity and type 2 diabetes. Journal of Diabetes 2012 4 196. (doi:10.1111/j.1753-0407.2012. 00194.x)
5. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE & Mantzoros CS. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012 61 1725-1738. (doi:10.1016/j.metabol.2012.09.002)
6. Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK, Kim JG, Lee IK & Park KG. Serum irisin levels in new-onset type 2 diabetes. Diabetes Research and Clinical Practice 2013 100 96-101. (doi:10.1016/j.diabres.2013.01.007)
7. Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW, Tavintharan S, Sum CF & Lim SC. Lower circulating irisin is associated with type 2 diabetes mellitus. Journal of Diabetes and its Complications 2013 27 365-369. (doi:10.1016/j.jdiacomp. 2013.03.002)
8. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P & Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity - correlation with body mass index. Peptides 2013 39 C 125-130. (doi:10.1016/j.peptides. 2012.11.014)
9. Kelly DP. Medicine. Irisin, light my fire. Science 2012 336 42-43. (doi:10.1126/science.1221688)
10. Hansen J, Brandt C, Nielsen AR, Hojman P, Whitham M, Febbraio MA, Pedersen BK & Plomgaard P. Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine. Endocrinology 2011 152 164-171. (doi:10.1210/en. 2010-0868)
11. Hittel DS, Axelson M, Sarna N, Shearer J, Huffman KM & Kraus WE. Myostatin decreases with aerobic exercise and associates with insulin resistance. Medicine and Science in Sports and Exercise 2010 42 2023-2029. (doi:10.1249/MSS. 0b013e3181e0b9a8)
12. Shan T, Liang X, Bi P & Kuang S. Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1a-Fndc5 pathway in muscle. FASEB Journal 2013 27 1981-1989. (doi:10.1096/fj.12-225755)
13. Vamvini MT, Aronis KN, Chamberland JP & Mantzoros CS. Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin A and follistatin but not myostatin in healthy males. Journal of Clinical Endocrinology and Metabolism 2011 96 3416-3423. (doi:10.1210/jc. 2011-1665)
14. Lee SJ, Lee YS, Zimmers TA, Soleimani A, Matzuk MM, Tsuchida K, Cohn RD & Barton ER. Regulation of muscle mass by follistatin and activins. Molecular Endocrinology 2010 24 1998-2008. (doi:10.1210/me.2010-0127)
15. Argiles JM, Orpi M, Busquets S & Lopez-Soriano FJ. Myostatin: more than just a regulator of muscle mass. Drug Discovery Today 2012 17 702-709. (doi:10.1016/j.drudis.2012.02.001)
16. Hamnvik OP, Liu X, Petrou M, Gong H, Chamberland JP, Kim EH, Christophi CA, Kales SN, Christiani DC & Mantzoros CS. Soluble leptin receptor and leptin are associated with baseline adiposity and metabolic risk factors, and predict adiposity, metabolic syndrome, and glucose levels at 2-year follow-up: the Cyprus Metabolism Prospective Cohort Study. Metabolism 2011 60 987-993. (doi:10.1016/j.metabol.2010.09.009)
17. Brinkoetter M, Magkos F, Vamvini M & Mantzoros CS. Leptin treatment reduces body fat but does not affect lean body mass or the myostatin- follistatin-activin axis in lean hypoleptinemic women. American Journal of Physiology. Endocrinology and Metabolism 2011 301 E99-E104. (doi:10.1152/ ajpendo.00146.2011)
18. Pedersen BK & Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nature Reviews. Endocrinology 2012 8 457-465. (doi:10.1038/nrendo.2012.49)
19. Roberts MD, Bayless DS, Company JM, Jenkins NT, Padilla J, Childs TE, Martin JS, Dalbo VJ, Booth FW, Rector RS et al. Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats. Metabolism 2013 62 1052-1056. (doi:10.1016/j.metabol. 2013.02.002)
20. Swick AG, Orena S & O'Connor A. Irisin levels correlate with energy expenditure in a subgroup of humans with energy expenditure greater than predicted by fat free mass. Metabolism 2013 62 1070-1073. (doi:10.1016/j. metabol.2013.02.012)
21. Fain JN, Company JM, Booth FW, Laughlin MH, Padilla J, Jenkins NT, Bahouth SW & Sacks HS. Exercise training does not increase muscle FNDC5 protein or mRNA expression in pigs. Metabolism 2013 62 1503-1511. (doi:10.1016/j.metabol.2013. 05.021)
22. Moon HS, Dincer F & Mantzoros CS. Pharmacological concentrations of irisin increase cell proliferation without influencing markers of neurite outgrowth and synaptogenesis in mouse H19-7 hippocampal cell lines. Metabolism 2013 62 1131-1136. (doi:10.1016/j.metabol.2013.04.007)
23. Polyzos SA, Kountouras J, Shields K & Mantzoros CS. Irisin: a renaissance in metabolism? Metabolism 2013 62 1037-1044. (doi:10.1016/j.metabol. 2013.04.008)
24. de Kretser DM, Hedger MP, Loveland KL & Phillips DJ. Inhibins, activins and follistatin in reproduction. Human Reproduction Update 2002 8 529-541. (doi:10.1093/humupd/8.6.529)
25. Nakatani M, Kokubo M, Ohsawa Y, Sunada Y & Tsuchida K. Follistatin-derived peptide expression in muscle decreases adipose tissue mass and prevents hepatic steatosis. American Journal of Physiology. Endocrinology and Metabolism 2011 300 E543-E553. (doi:10.1152/ajpendo.00430.2010)
26. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, Ricart W & Fernandez-Real JM. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. Journal of Clinical Endocrinology andMetabolism 2013 98 E769-E778. (doi:10.1210/jc.2012-2749)
27. Roca-Rivada A, Castelao C, Senin LL, Landrove MO, Baltar J, Belen Crujeiras A, Seoane LM, Casanueva FF & Pardo M. FNDC5/irisin is not only a myokine but also an adipokine. PLoS ONE 2013 8 e60563. (doi:10.1371/journal. pone.0060563)
28. McPherron AC. Metabolic functions of myostatin and Gdf11. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry 2010 10 217-231. (doi:10.2174/187152210793663810)
29. Dani C. Activins in adipogenesis and obesity. International Journal of Obesity 2013 37 163-166. (doi:10.1038/ijo.2012.28) Diseases